Table 3.
Effect of ZG02-ME on serum insulin, leptin, and C-peptide levels in diabetic-obese (db/db) mice.
| Treatment | Dose (mg/kg Body Weight) | Hormone Parameters (ng/mL) | ||
|---|---|---|---|---|
| Insulin | Leptin | C-peptide | ||
| Normal control | – | 2.7 ± 0.2 | 28.6 ± 2.1 | 1.66 ± 0.23 |
| Vehicle control | – | 3.4 ± 0.4 # | 45.5 ± 2.6 # | 1.88 ± 0.25 # |
| ZG02-ME | 1 | 3.1 ± 0.5 | 42.6 ± 5.2 | 1.75 ± 0.18 |
| 3 | 2.9 ± 0.5 * | 38.4 ± 3.9 * | 1.72 ± 0.26 * | |
| 5 | 2.7 ± 0.6 * | 35.4 ± 2.4 * | 1.69 ± 0.16 * | |
The db/m mice were intragastrically administrated daily with normal saline containing 0.01% DMSO, as the vehicle, for 4 weeks (normal control). The db/db mice were intragastrically administrated daily with vehicle (vehicle control) or ZG02-ME, respectively, for four weeks. The serum insulin, leptin, and C-peptide levels were measured as described in the methods. Data are shown as mean ± SD of (n = 8). # p < 0.05 vs. normal control, and * p < 0.05 vs. vehicle-treated control as determined by one-way Student’s t-test.